BioCentury This Week analyzes the ins and outs of the Inflation Reduction Act
By Jeff Cranmer, Executive Editor
December 19, 2022 8:47 PM UTC
A strategy for navigating the Inflation Reduction Act is essential for every biopharma company, regardless of size or location, Washington Editor Steve Usdin said on a special edition of the BioCentury This Week podcast. Usdin and his BioCentury colleagues discuss why creating an IRA strategy is so complex, when and how CMS is going to set prices for drugs selected for scrutiny and what the chances are that the act can be repealed or modified.
For information on how to sponsor BioCentury This Week and The BioCentury Show, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.
